Ixchelsis Limited is an independent biotechnology company based in Discovery Park, Sandwich, UK. Ixchelsis has achieved positive proof of concept with IX-01, an investigational compound, originally discovered at Pfizer’s, Sandwich, UK, R&D site. IX-01 is an Oxytocin receptor antagonist with the potential to treat the male sexual health indication, premature ejaculation (PE).

PE is a highly distressing medical condition with limited treatment options in the EU and currently no approved therapies in the US. Ixchelsis has a highly experienced management team with an excellent track record both in clinical development and the field of male sexual health. Ixchelsis raised a total of $26 million financing from TVM Life Science Ventures VII and Pfizer Ventures.